A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Clinical trial NCT04951219 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04951219
- Sponsor
- Madrigal Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-09
- Primary completion
- 2027-03-01
- Enrollment
- 810
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.